Efficacy and safety of nivolumab in patients with BRAF V600 mutant and BRAF wild-type advanced melanoma: A pooled analysis of 4 clinical trials

JAMA Oncology

Volumn 1, Issue 4, 2015, Pages 433-440

  Larkin, James ^a   Lao, Christopher D ^b,c   Urba, Walter J ^d   McDermott, David F ^e   Horak, Christine ^f   Jiang, Joel ^f   Wolchok, Jedd D ^g,h  

^a ROYAL MARSDEN HOSPITAL   (United Kingdom)

^b UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

^d EARLE A CHILES RESEARCH INSTITUTE   (United States)

^e BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^f BRISTOL MYERS SQUIBB   (United States)

^g MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^h WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; B RAF KINASE; BRAF PROTEIN, HUMAN; IPILIMUMAB; MONOCLONAL ANTIBODY; NIVOLUMAB; PDCD1 PROTEIN, HUMAN; PROGRAMMED DEATH 1 RECEPTOR; PROTEIN KINASE INHIBITOR; TUMOR MARKER;

ADULT; AGED; ANTAGONISTS AND INHIBITORS; CANCER STAGING; CLINICAL TRIAL (TOPIC); DISEASE COURSE; DRUG ADMINISTRATION; DRUG EFFECTS; ENZYMOLOGY; FEMALE; GENETIC PREDISPOSITION; GENETICS; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; KAPLAN MEIER METHOD; MALE; MELANOMA; META ANALYSIS; METABOLISM; MIDDLE AGED; MUTATION; PATHOLOGY; PHENOTYPE; RETROSPECTIVE STUDY; SECONDARY; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; TIME FACTOR; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; BIOMARKERS, TUMOR; CLINICAL TRIALS AS TOPIC; DISEASE PROGRESSION; DRUG ADMINISTRATION SCHEDULE; FEMALE; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INFUSIONS, INTRAVENOUS; KAPLAN-MEIER ESTIMATE; MALE; MELANOMA; MIDDLE AGED; MUTATION; NEOPLASM STAGING; PHENOTYPE; PROGRAMMED CELL DEATH 1 RECEPTOR; PROTEIN KINASE INHIBITORS; PROTO-ONCOGENE PROTEINS B-RAF; RETROSPECTIVE STUDIES; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84980602745     PISSN: 23742437     EISSN: 23742445     Source Type: Journal    
DOI: 10.1001/jamaoncol.2015.1184     Document Type: Article

References (28)

1. Hodi FS, O'Day SJ, McDermott DF, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363(8):711-723.
2. Robert C, Thomas L, Bondarenko I, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med. 2011;364(26):2517-2526.
3. Shtivelman E, Davies MQ, Hwu P, et al. Pathways and therapeutic targets in melanoma. Oncotarget. 2014;5(7):1701-1752.
4. Chapman PB, Hauschild A, Robert C, et al; BRIM-3 Study Group. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364(26):2507-2516.
5. Flaherty KT, Robert C, Hersey P, et al; METRIC Study Group. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med. 2012;367(2):107-114.
6. Hauschild A, Grob JJ, Demidov LV, et al. Dabrafenib in BRAF-mutated metastatic melanoma: a multicentre, open-label, phase 3 randomised controlled trial. Lancet. 2012;380(9839):358-365.
7. Larkin J, Ascierto PA, Dréno B, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med. 2014;371(20):1867-1876.
8. Long GV, Stroyakovskiy D, Gogas H, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med. 2014;371(20):1877-1888.
9. Robert C, Karaszewska B, Schachter J, et al. Improved overall survival in melanoma with combined dabrafenib and trametinib. N Engl J Med. 2015;372(1):30-39.
10. Wolchok JD, Hodi FS, Weber JS, et al. Development of ipilimumab: a novel immunotherapeutic approach for the treatment of advanced melanoma. Ann N Y Acad Sci. 2013;1291(1):1-13.
11. Topalian SL, Weiner GJ, Pardoll DM. Cancer immunotherapy comes of age. J Clin Oncol. 2011;29(36):4828-4836.
12. Deeks ED. Nivolumab: a review of its use in patients with malignant melanoma. Drugs. 2014;74(11):1233-1239.
13. Poole RM. Pembrolizumab: first global approval. Drugs. 2014;74(16):1973-1981.
14. OPDIVO. (nivolumab) Prescribing Information. Princeton, NJ: Bristol-Myers Squibb Co. http://packageinserts.bms.com/pi/pi-opdivo.pdf. Accessed April 23, 2015
15. Shahabi V, Whitney G, Hamid O, et al. Assessment of association between BRAF-V600E mutation status in melanomas and clinical response to ipilimumab. Cancer Immunol Immunother. 2012;61(5):733-737.
16. Margolin KA, Tarhini A, Rao S, et al. Effectiveness and safety of ipilimumab therapy in advanced melanoma: evidence from clinical practice sites in the US. J Community Support Oncol. 2015;13(4):131-138.
17. Sznol M, Kluger HM, Callahan MK, et al. Survival, response duration, and activity by BRAF mutation (MT) status of nivolumab (NIVO, anti-PD-1, BMS-936558, ONO-4538) and ipilimumab (IPI) concurrent therapy in advanced melanoma. J Clin Oncol. 2014;32(5s):LBA9003.
18. D'Angelo SP, Larkin J, Weber J, et al. Efficacy and safety of nivolumab vs investigator's choice chemotherapy (ICC) in subgroups of patients with advanced melanoma after prior anti-CTLA-4 therapy. Presented at the Society for Melanoma Research (SMR) 2014 Congress; November 13-16, 2014; Zurich, Switzerland.
19. Topalian SL, Sznol M, McDermott DF, et al. Survival, durable tumor remission, and long-term safety in patients with advanced melanoma receiving nivolumab. J Clin Oncol. 2014;32(10):1020-1030.
20. ClinicalTrials.gov. PH1 Biomarker study of nivolumab and ipilimumab and nivolumab in combination with ipilimumab in advanced melanoma (PD-1). https://clinicaltrials.gov/ct2/show/NCT01621490. Accessed April 23, 2015.
21. Wolchok JD, Kluger H, Callahan MK, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369(2):122-133.
22. Weber JS, D'Angelo SP, Minor D, et al. Nivolumab vs chemotherapy in patients with advanced melanoma who progressed after anti-CTLA-4 treatment (CheckMate 037): a randomised, controlled, open-label, phase 3 trial. Lancet Oncol. 2015;16(4):375-384.
23. Cancer Therapy Evaluation Program (CTEP) Common Terminology Criteria for Adverse Event v3.0 (CTCAE). Washington, DC: Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Department of Health and Human Services; August 9, 2006. http://ctep.cancer.gov/protocolDevelopment/electronic-applications /docs/ctcaev3.pdf. Accessed December 19, 2014.
24. Robert C, Ribas A, Wolchok JD, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet. 2014;384(9948):1109-1117.
25. Robert C, Long GV, Brady B, et al. Nivolumab in previously untreated melanoma without BRAF mutation. N Engl J Med. 2015;372(4):320-330.
26. Kaufman HL, Kirkwood JM, Hodi FS, et al. The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma. Nat Rev Clin Oncol. 2013;10(10):588-598.
27. Ackerman A, Klein O, McDermott DF, et al. Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors. Cancer. 2014;120(11):1695-1701.
28. Ascierto PA, Margolin K. Ipilimumab before BRAF inhibitor treatment may be more beneficial than vice versa for the majority of patients with advanced melanoma. Cancer. 2014;120(11):1617-1619.